PBAC advice rejected and buried

By Megan Brodie 1 year ago | In Companies, Products, Reimbursement
  • 1 year ago

14 November 2022 The PBAC recommended AstraZeneca’s high-cost Covid injectable EVUSHELD (tixagevimab + cilgavimab) be…

This is subscriber-only content. Please login to continue reading.